Callender D P, Jayaprakash N, Bell A, Petraitis V, Petraitiene R, Candelario M, Schaufele R, Dunn J M, Sei S, Walsh T J, Balis F M
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
Antimicrob Agents Chemother. 1999 Apr;43(4):972-4. doi: 10.1128/AAC.43.4.972.
The pharmacokinetic profile of oral zidovudine entrapped in a 50:50 polyactide-coglycolide matrix (nanospheres) was compared to those of standard oral and parenteral zidovudine formulations in rabbits. The bioavailability of zidovudine nanospheres at 50 mg/kg of body weight was 76%, and this dose achieved prolonged exposure to zidovudine compared to standard formulations without an increase in the drug's peak concentration.
将包裹于50:50聚丙交酯-乙交酯基质（纳米球）中的口服齐多夫定的药代动力学特征，与兔体内标准口服及肠胃外齐多夫定制剂的药代动力学特征进行了比较。体重50 mg/kg时，齐多夫定纳米球的生物利用度为76%，与标准制剂相比，该剂量实现了对齐多夫定的延长暴露，且未增加药物的峰值浓度。
